RCUSHealthcare · BiotechnologyThe 13 Wall Street analysts covering Arcus Biosciences, Inc. hold a median 12-month price target of $43 — +39.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 58 of 100 as at 21 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Arcus Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (99): The shares have been drifting up relative to others.
Issuance (25): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on RCUS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +39.9% from it.
Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Aug 2026 | Wedbush | Maintains | Outperform | $41 → $43 |
| 6 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | $23 → $26 |
| 20 July 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 20 July 2026 | HC Wainwright & Co. | Maintains | Buy | $32 → $45 |
| 4 June 2026 | LifeSci Capital | Initiates | Outperform | — |
| 4 June 2026 | LifeSci Capital | Initiates | Outperform | $46 |
| 18 May 2026 | Truist Securities | Assumes | Buy | $30 → $35 |
| 11 May 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 7 May 2026 | Goldman Sachs | Maintains | Buy | — |
| 2 Apr 2026 | Wedbush | Maintains | Outperform | — |
| 5 Mar 2026 | Citigroup | Maintains | Buy | — |
| 2 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 Mar 2026 | Leerink Partners | Maintains | Outperform | — |
| 12 Feb 2026 | Wells Fargo | Downgrade | Equal-Weight | — |
| 13 Jan 2026 | Goldman Sachs | Upgrade | Buy | — |
| 8 Jan 2026 | Morgan Stanley | Downgrade | Equal-Weight | — |
| 12 Dec 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 28 Nov 2025 | B of A Securities | Maintains | Neutral | — |
| 30 Oct 2025 | Goldman Sachs | Maintains | Neutral | — |
| 29 Oct 2025 | Citigroup | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RCUS appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 92% of US stocks
Cheaper than 7% of US stocks
Cheaper than 13% of US stocks
Cheaper than 81% of US stocks
Higher than 3% of US stocks
Higher than 5% of US stocks
Higher than 10% of US stocks
Higher than 30% of US stocks
Higher than 14% of US stocks
Higher than 14% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Arcus Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Arcus Biosciences announced that its Compensation Committee granted a new employee options to purchase 2,850 shares of the company's common stock at an exercise price of $28.72 per share, as a new employment inducement grant.
Why it matters — RCUS watchers would note this as a standard employment inducement grant, which reflects routine share-based compensation for a newly hired employee.
Arcus Biosciences reported its second-quarter financial results and, during its earnings call, outlined plans to expand development of its casdatifan cancer program across multiple lines of clear cell renal cell carcinoma. The company also provided updates on its pancreatic cancer and immunology pipelines.
Why it matters — RCUS watchers would care because the company's expansion of the casdatifan program into multiple ccRCC treatment lines signals a key strategic focus for its oncology pipeline.
Arcus Biosciences, Inc. (RCUS) held its Q2 2026 earnings call, and the transcript of that call has been published on Seeking Alpha.
Why it matters — A RCUS watcher would look to this earnings call transcript for management's commentary on the company's quarterly performance and outlook.
Arcus Biosciences reported a Q2 loss of $0.72 per share, narrower than the Zacks Consensus Estimate of a $0.98 loss, and compared with break-even per share a year ago. The company also topped revenue estimates for the quarter.
Why it matters — The narrower-than-expected loss and revenue beat provide an updated picture of Arcus Biosciences' second-quarter financial performance for those following the company.
Arcus Biosciences reported financial results for the second quarter ended June 30, 2026, and provided an update on its clinical-stage investigational molecules and discovery programs. The company also noted a recent publication in Nature highlighting its research commitment.
Why it matters — RCUS watchers would care because the quarterly results and pipeline update offer a read on the company's financial position and the progress of its cancer and inflammation-focused programs.
The 13 Wall Street analysts covering Arcus Biosciences, Inc. have a median 12-month price target of $43, with estimates ranging from $23 to $47. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 13 analysts covering Arcus Biosciences, Inc., 10 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Arcus Biosciences, Inc. 58 out of 100 across roughly 4,600 US stocks as at 21 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 21 Aug 2026, Arcus Biosciences, Inc. ranks 58 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).
No one can know that. What the data says: the median 12-month target from 13 analysts implies +39.9% from the last close, and Ticker Nerd's factor model ranks Arcus Biosciences, Inc. 58 out of 100 as at 21 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Arcus Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RCUS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $23 to $47 over the next 12 months.
Arcus Biosciences, Inc. returned +189.8% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Arcus Biosciences Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies.
The most recent item we track (Business Wire, 11 Aug 2026): "Arcus Biosciences Announces New Employment Inducement Grants". Arcus Biosciences announced that its Compensation Committee granted a new employee options to purchase 2,850 shares of the company's common stock at an exercise price of $28.72 per share, as a new employment inducement grant.
Arcus Biosciences Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. Focusing primarily on immuno-oncology, the company aims to harness the body's own immune system to target and eliminate cancer cells. Arcus Biosciences' pipeline includes a variety of monoclonal antibodies, small molecules, and combination therapies that address different aspects of cancer's complex biology. One of its core strategies is to develop next-generation treatments that can potentially improve upon existing therapies, enhancing efficacy while minimizing side effects. Operating in an industry marked by rapid scientific advancements, Arcus Biosciences plays a critical role in the ongoing pursuit of more effective cancer treatments. Its efforts contribute to the diversification of therapeutic options available to clinicians, offering hope to patients managing the challenges of cancer. Through strategic partnerships and robust research initiatives, Arcus Biosciences continues to expand its impact within the highly competitive biopharmaceutical sector, underscoring the importance of innovation in the battle against cancer.
CEO Dr. Terry J. Rosen Ph.D. · 601 employees · United States · https://arcusbio.com